{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:24:56Z","timestamp":1791645896913,"version":"4.3.4"},"reference-count":141,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/100016021","name":"Corona-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016021","id-type":"DOI","asserted-by":"publisher"}]},{"name":"START program of the Faculty of Medicine of the RWTH Aachen University","award":["105\/20"],"award-info":[{"award-number":["105\/20"]}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["Project 2020_EKEA.60"],"award-info":[{"award-number":["Project 2020_EKEA.60"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["322900939"],"award-info":[{"award-number":["322900939"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["403224013"],"award-info":[{"award-number":["403224013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2020T020"],"award-info":[{"award-number":["2020T020"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Patients with CKD display a significantly higher risk of cardiovascular and thromboembolic complications, with around half of patients with advanced CKD ultimately dying of cardiovascular disease. Paradoxically, these patients also have a higher risk of hemorrhages, greatly complicating patient therapy. Platelets are central to hemostasis, and altered platelet function resulting in either platelet hyper- or hyporeactivity may contribute to thrombotic or hemorrhagic complications. Different molecular changes have been identified that may underlie altered platelet activity and hemostasis in CKD. In this study, we summarize the knowledge on CKD-induced aberrations in hemostasis, with a special focus on platelet abnormalities. We also discuss how prominent alterations in vascular integrity, coagulation, and red blood cell count in CKD may contribute to altered hemostasis in these patients who are high risk. Furthermore, with patients with CKD commonly receiving antiplatelet therapy to prevent secondary atherothrombotic complications, we discuss antiplatelet treatment strategies and their risk versus benefit in terms of thrombosis prevention, bleeding, and clinical outcome depending on CKD stage. This reveals a careful consideration of benefits versus risks of antiplatelet therapy in patients with CKD, balancing thrombotic versus bleeding risk. Nonetheless, despite antiplatelet therapy, patients with CKD remain at high cardiovascular risk. Thus, deep insights into altered platelet activity in CKD and underlying mechanisms are important for the optimization and development of current and novel antiplatelet treatment strategies, specifically tailored to these patients who are high risk. Ultimately, this review underlines the importance of a closer investigation of altered platelet function, hemostasis, and antiplatelet therapy in patients with CKD.<\/jats:p>","DOI":"10.2215\/cjn.04100321","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T13:15:17Z","timestamp":1636377317000},"page":"155-170","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":80,"title":["Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy"],"prefix":"10.2215","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct03796156","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03357874","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Constance C.F.M.J.","family":"Baaten","sequence":"first","affiliation":[{"name":"Institute for Molecular Cardiovascular Research, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen, Aachen, Germany"},{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas R.","family":"Schr\u00f6er","sequence":"additional","affiliation":[{"name":"Institute for Molecular Cardiovascular Research, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Clinical Immunology, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Jankowski","sequence":"additional","affiliation":[{"name":"Institute for Molecular Cardiovascular Research, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen, Aachen, Germany"},{"name":"Department of Pathology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Noels","sequence":"additional","affiliation":[{"name":"Institute for Molecular Cardiovascular Research, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen, Aachen, Germany"},{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jth.12652","article-title":"Kidney disease and risk of venous thromboembolism: A nationwide population-based case-control study","volume":"12","author":"Christiansen","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1161\/01.RES.0000160077.17427.57","article-title":"Platelets and chemokines in atherosclerosis: Partners in crime","volume":"96","author":"Weber","year":"2005","journal-title":"Circ Res"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2003-40673","article-title":"Role of platelets in the pathophysiology of acute coronary syndrome","volume":"3","author":"Massberg","year":"2003","journal-title":"Semin Vasc Med"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","article-title":"Platelet dysfunction in renal failure","volume":"30","author":"Boccardo","year":"2004","journal-title":"Semin Thromb Hemost"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: A cohort study","volume":"16","author":"Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40697-014-0021-x","article-title":"The three-year incidence of major hemorrhage among older adults initiating chronic dialysis","volume":"1","author":"Sood","year":"2014","journal-title":"Can J Kidney Health Dis"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1681\/ASN.V25961","article-title":"Minimizing hemorrhagic complications in dialysis patients","volume":"2","author":"Lohr","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2369-14-15","article-title":"The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: A population-based cohort study","volume":"14","author":"Kuo","year":"2013","journal-title":"BMC Nephrol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41569-018-0110-0","article-title":"Platelet biology and functions: New concepts and clinical perspectives","volume":"16","author":"van der Meijden","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.blre.2013.12.001","article-title":"Targeting platelet receptor function in thrombus formation: The risk of bleeding","volume":"28","author":"Swieringa","year":"2014","journal-title":"Blood Rev"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/09537104.2010.522629","article-title":"Nitric oxide at a glance","volume":"22","author":"Naseem","year":"2011","journal-title":"Platelets"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.05.002","article-title":"Extracellular ATP metabolism on vascular endothelial cells: A pathway with pro-thrombotic and anti-thrombotic molecules","volume":"75","author":"Fuentes","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5482\/HAMO-14-12-0081","article-title":"Interaction of von Willebrand factor with platelets and the vessel wall","volume":"35","author":"Ruggeri","year":"2015","journal-title":"Hamostaseologie"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2003-03-0889","article-title":"Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood","volume":"103","author":"Siljander","year":"2004","journal-title":"Blood"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1096\/fj.04-1940fje","article-title":"Adhesion of human and mouse platelets to collagen under shear: A unifying model","volume":"19","author":"Auger","year":"2005","journal-title":"FASEB J"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/09537104.2016.1240768","article-title":"The nuts and bolts of the platelet release reaction","volume":"28","author":"Joshi","year":"2017","journal-title":"Platelets"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1538-7836.2008.03041.x","article-title":"Multiple ways to switch platelet integrins on and off","volume":"6","author":"Cosemans","year":"2008","journal-title":"J Thromb Haemost"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","article-title":"Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis","volume":"27","author":"Mackman","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jth.12045","article-title":"Platelet-based coagulation: Different populations, different functions","volume":"11","author":"Heemskerk","year":"2013","journal-title":"J Thromb Haemost"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1681\/ASN.2020101440","article-title":"Platelet function in chronic kidney disease: A systematic review and meta-analysis","volume":"32","author":"Baaten","journal-title":"J Am Soc Nephrol"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1742-1241.2012.02974.x","article-title":"Risk factors influencing the outcome of peptic ulcer bleeding in end stage renal disease after initial endoscopic haemostasis","volume":"66","author":"Lin","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1159\/000502526","article-title":"Changes in FGF-23, neutrophil\/platelet activation markers, and angiogenin in advanced chronic kidney disease and their effect on arterial stiffness","volume":"44","author":"Choi","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"e014294","DOI":"10.1136\/bmjopen-2016-014294","article-title":"Blood coagulation system in patients with chronic kidney disease: A prospective observational study","volume":"7","author":"Huang","year":"2017","journal-title":"BMJ Open"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ki.2012.130","article-title":"Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia","volume":"82","author":"Daugirdas","year":"2012","journal-title":"Kidney Int"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-0040-1708841","article-title":"Platelets in advanced chronic kidney disease: Two sides of the coin","volume":"46","author":"Lutz","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.2830500303","article-title":"Reticulated platelets in uremic patients: Effect of hemodialysis and continuous ambulatory peritoneal dialysis","volume":"50","author":"T\u00e0ssies","year":"1995","journal-title":"Am J Hematol"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/09537100801990582","article-title":"\u201cMessage in the platelet\u201d: More than just vestigial mRNA!","volume":"19","author":"Harrison","year":"2008","journal-title":"Platelets"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2141.1998.00563.x","article-title":"Flow cytometric analysis of reticulated platelets: Evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes","volume":"100","author":"Robinson","year":"1998","journal-title":"Br J Haematol"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000166482","article-title":"Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase","volume":"1","author":"Eknoyan","year":"1981","journal-title":"Am J Nephrol"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-14-72","article-title":"Coagulation activation, depletion of platelet granules and endothelial integrity in case of uraemia and haemodialysis treatment","volume":"14","author":"Schoorl","year":"2013","journal-title":"BMC Nephrol"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000184118","article-title":"Platelet count and thrombopoietic activity in patients with chronic renal failure","volume":"45","author":"Gafter","year":"1987","journal-title":"Nephron"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tmrv.2004.03.003","article-title":"Relationship between platelet count and bleeding risk in thrombocytopenic patients","volume":"18","author":"Slichter","year":"2004","journal-title":"Transfus Med Rev"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1055\/s-0040-1705138","article-title":"Assessment of thrombotic and bleeding tendency in two mouse models of chronic kidney disease: Adenine-diet and 5\/6th nephrectomy","volume":"4","author":"Makhloufi","year":"2020","journal-title":"TH Open"},{"key":"B35-20241015","first-page":"335","article-title":"Platelet function in patients on long term peritoneal dialysis","volume":"6","author":"Lindsay","year":"1976","journal-title":"Clin Nephrol"},{"key":"B36-20241015","first-page":"84","article-title":"Adhesiveness of blood platelets in uremia","volume":"15","author":"Salzman","year":"1966","journal-title":"Thromb Diath Haemorrh"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000169033","article-title":"Plasma phospholipids and platelet function in uremic patients","volume":"16","author":"Vecino","year":"1996","journal-title":"Am J Nephrol"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000182894","article-title":"Comprehensive study of haemostasis in chronic uraemia","volume":"33","author":"Panicucci","year":"1983","journal-title":"Nephron"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/archinte.1970.00310110093013","article-title":"Uremic toxins and platelet function","volume":"126","author":"Horowitz","year":"1970","journal-title":"Arch Intern Med"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jcp.25.9.745","article-title":"A clinical and experimental study of platelet function in chronic renal failure","volume":"25","author":"Evans","year":"1972","journal-title":"J Clin Pathol"},{"key":"B41-20241015","doi-asserted-by":"crossref","first-page":"e0212237","DOI":"10.1371\/journal.pone.0212237","article-title":"Evaluation of hemostasis in patients with end-stage renal disease","volume":"14","author":"G\u00e4ckler","year":"2019","journal-title":"PLoS One"},{"key":"B42-20241015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0049-3848(83)90080-4","article-title":"Synthesis of thromboxane B2 in uraemia and the effects of dialysis","volume":"30","author":"Winter","year":"1983","journal-title":"Thromb Res"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1139\/Y10-111","article-title":"Increased nitric oxide production in platelets from severe chronic renal failure patients","volume":"89","author":"Siqueira","year":"2011","journal-title":"Can J Physiol Pharmacol"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000181641","article-title":"Platelets and platelet function in patients with chronic uremia on maintenance hemodialysis","volume":"23","author":"J\u00f8rgensen","year":"1979","journal-title":"Nephron"},{"key":"B45-20241015","first-page":"300","article-title":"Elevated platelet-free calcium in uraemia","volume":"74","author":"Moosa","year":"1990","journal-title":"Br J Haematol"},{"key":"B46-20241015","first-page":"979","article-title":"Platelet function in renal failure","volume":"62","author":"Surie","year":"1974","journal-title":"Indian J Med Res"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-0038-1647640","article-title":"Platelet function and the bleeding time in progressive renal failure","volume":"60","author":"Gordge","year":"1988","journal-title":"Thromb Haemost"},{"key":"B48-20241015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1076029613490828","article-title":"Platelet hyperaggregability is highly prevalent in patients with chronic kidney disease: An underestimated risk indicator of thromboembolic events","volume":"21","author":"Yagmur","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"key":"B49-20241015","first-page":"16704","article-title":"Alteration of circulatory platelet microparticles and endothelial microparticles in patients with chronic kidney disease","volume":"8","author":"Lu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B50-20241015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.blre.2017.07.004","article-title":"Platelet populations and priming in hematological diseases","volume":"31","author":"Baaten","year":"2017","journal-title":"Blood Rev"},{"key":"B51-20241015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/toxins10010033","article-title":"Biochemical and clinical impact of organic uremic retention solutes: A comprehensive update","volume":"10","author":"Vanholder","year":"2018","journal-title":"Toxins (Basel)"},{"key":"B52-20241015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.fjc.0000171753.43564.7c","article-title":"Polyamines inhibit both platelet aggregation and glycoprotein IIb\/IIIa activation","volume":"46","author":"Corona-de-la-Pe\u00f1a","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"B53-20241015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0049-3848(99)00212-1","article-title":"On the mechanism of the spermine-exerted inhibition on alpha-thrombin-induced platelet activation","volume":"98","author":"Via","year":"2000","journal-title":"Thromb Res"},{"key":"B54-20241015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0304-4165(86)90315-6","article-title":"Differential effects of spermine on aggregation, inositol phosphate formation and protein phosphorylation in human platelets in response to thrombin, arachidonic acid and lysophosphatidic acid","volume":"883","author":"Israels","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"B55-20241015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0024-3205(76)90398-2","article-title":"Polyamines and platelet aggregation","volume":"19","author":"Rennert","year":"1976","journal-title":"Life Sci"},{"key":"B56-20241015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","article-title":"Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk","volume":"165","author":"Zhu","year":"2016","journal-title":"Cell"},{"key":"B57-20241015","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2016-10-744060","article-title":"Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice","volume":"129","author":"Yang","year":"2017","journal-title":"Blood"},{"key":"B59-20241015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/0002-9343(85)90051-8","article-title":"Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis","volume":"79","author":"Di Minno","year":"1985","journal-title":"Am J Med"},{"key":"B60-20241015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/toxins12040227","article-title":"Inflammation and premature ageing in chronic kidney disease","volume":"12","author":"Ebert","year":"2020","journal-title":"Toxins (Basel)"},{"key":"B61-20241015","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.2019000200","article-title":"TNF-\u03b1-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging","volume":"134","author":"Davizon-Castillo","year":"2019","journal-title":"Blood"},{"key":"B62-20241015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.atherosclerosis.2008.04.001","article-title":"The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients","volume":"202","author":"Gori","year":"2009","journal-title":"Atherosclerosis"},{"key":"B63-20241015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000327131","article-title":"Does uremia cause vascular dysfunction?","volume":"34","author":"Brunet","year":"2011","journal-title":"Kidney Blood Press Res"},{"key":"B64-20241015","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00787.2016","article-title":"Vasculopathy in the setting of cardiorenal syndrome: Roles of protein-bound uremic toxins","volume":"313","author":"Guo","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B65-20241015","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1046\/j.1523-1755.63.s84.15.x","article-title":"Endothelial permeability in uremia","volume":"84","author":"Harper","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"B66-20241015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ckj\/sfz076","article-title":"Circulating active von Willebrand factor levels are increased in chronic kidney disease and end-stage renal disease","volume":"13","author":"van der Vorm","year":"2019","journal-title":"Clin Kidney J"},{"key":"B67-20241015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ki.2013.133","article-title":"Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway","volume":"84","author":"Gondouin","year":"2013","journal-title":"Kidney Int"},{"key":"B68-20241015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00204-018-2328-3","article-title":"Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor\/nuclear factor-kappa B signaling pathway in human endothelial cells","volume":"93","author":"Addi","year":"2019","journal-title":"Arch Toxicol"},{"key":"B69-20241015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2017-06-742676","article-title":"Platelets and vascular integrity: How platelets prevent bleeding in inflammation","volume":"131","author":"Ho-Tin-No\u00e9","year":"2018","journal-title":"Blood"},{"key":"B70-20241015","doi-asserted-by":"crossref","first-page":"e67799","DOI":"10.1371\/journal.pone.0067799","article-title":"Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: A prospective analysis","volume":"8","author":"Milburn","year":"2013","journal-title":"PLoS One"},{"key":"B71-20241015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1681\/ASN.V1261255","article-title":"Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis","volume":"12","author":"Segarra","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B72-20241015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.CIR.0000042700.48769.59","article-title":"Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency","volume":"107","author":"Shlipak","year":"2003","journal-title":"Circulation"},{"key":"B73-20241015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0049-3848(97)00280-6","article-title":"Endothelial cell markers in chronic uremia: Relationship with hemostatic defects and severity of renal failure","volume":"88","author":"Mezzano","year":"1997","journal-title":"Thromb Res"},{"key":"B74-20241015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajh.2830310205","article-title":"Protein S and C antigen levels in proteinuric patients: Dependence on type of glomerular pathology","volume":"31","author":"Allon","year":"1989","journal-title":"Am J Hematol"},{"key":"B75-20241015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12882-019-1344-8","article-title":"Protein C and protein S deficiencies may be related to survival among hemodialysis patients","volume":"20","author":"Ichinose","year":"2019","journal-title":"BMC Nephrol"},{"key":"B76-20241015","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/ndt\/gfm884","article-title":"Altered fibrin clot properties in patients on long-term haemodialysis: Relation to cardiovascular mortality","volume":"23","author":"Undas","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B77-20241015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MBC.0b013e32833a9035","article-title":"The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome","volume":"21","author":"Undas","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B78-20241015","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1681\/ASN.2016030336","article-title":"Clot structure: A potent mortality risk factor in patients on hemodialysis","volume":"28","author":"Schuett","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B79-20241015","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/jth.14360","article-title":"Red blood cells: The forgotten player in hemostasis and thrombosis","volume":"17","author":"Weisel","year":"2019","journal-title":"J Thromb Haemost"},{"key":"B80-20241015","doi-asserted-by":"crossref","first-page":"39024","DOI":"10.1074\/jbc.M509045200","article-title":"Nitric oxide scavenging by red blood cells as a function of hematocrit and oxygenation","volume":"280","author":"Azarov","year":"2005","journal-title":"J Biol Chem"},{"key":"B81-20241015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bpj.2016.06.024","article-title":"The effect of hematocrit on platelet adhesion: Experiments and simulations","volume":"111","author":"Spann","year":"2016","journal-title":"Biophys J"},{"key":"B82-20241015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ki.1984.36","article-title":"Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency","volume":"25","author":"McGonigle","year":"1984","journal-title":"Kidney Int"},{"key":"B83-20241015","first-page":"170","article-title":"Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure","volume":"97","author":"Wallner","year":"1981","journal-title":"J Lab Clin Med"},{"key":"B84-20241015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0272-6386(04)00951-5","article-title":"Red blood cell survival in chronic renal failure","volume":"44","author":"Ly","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B85-20241015","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B86-20241015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0140-6736(82)90050-2","article-title":"Uraemic bleeding: Role of anaemia and beneficial effect of red cell transfusions","volume":"2","author":"Livio","year":"1982","journal-title":"Lancet"},{"key":"B87-20241015","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"B88-20241015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B89-20241015","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"B90-20241015","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.amjcard.2011.11.049","article-title":"Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting","volume":"109","author":"Toma","year":"2012","journal-title":"Am J Cardiol"},{"key":"B91-20241015","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.amjcard.2016.03.034","article-title":"Impact of anemia on platelet reactivity and ischemic and bleeding risk: From the assessment of dual antiplatelet therapy with drug-eluting stents study","volume":"117","author":"Giustino","year":"2016","journal-title":"Am J Cardiol"},{"key":"B92-20241015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/hrt.2010.220491","article-title":"High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention","volume":"97","author":"Breet","year":"2011","journal-title":"Heart"},{"key":"B93-20241015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/2048872615598631","article-title":"Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial","volume":"5","author":"Melloni","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B94-20241015","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jcin.2017.02.047","article-title":"Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A report from the PROMETHEUS study","volume":"10","author":"Baber","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"B95-20241015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: Phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B96-20241015","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ahj.2011.09.003","article-title":"Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study","volume":"162","author":"Woo","year":"2011","journal-title":"Am Heart J"},{"key":"B97-20241015","doi-asserted-by":"crossref","first-page":"8236903","DOI":"10.1155\/2016\/8236903","article-title":"Role of cilostazol therapy in hemodialysis patients with asymptomatic peripheral arterial disease: A retrospective cohort study","volume":"2016","author":"Lim","year":"2016","journal-title":"BioMed Res Int"},{"key":"B98-20241015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jjcc.2015.05.003","article-title":"Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease","volume":"67","author":"Ishii","year":"2016","journal-title":"J Cardiol"},{"key":"B99-20241015","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1021\/jm0603670","article-title":"Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects","volume":"49","author":"Chackalamannil","year":"2006","journal-title":"J Med Chem"},{"key":"B100-20241015","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.118.033580","article-title":"Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease","volume":"139","author":"Gurbel","year":"2019","journal-title":"Circulation"},{"key":"B101-20241015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5482\/hamo-14-10-0048","article-title":"Why we should not skip aspirin in cardiovascular prevention","volume":"36","author":"Schr\u00f6r","year":"2016","journal-title":"Hamostaseologie"},{"key":"B102-20241015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/jth.13211","article-title":"Antiplatelet effects of aspirin in chronic kidney disease patients","volume":"14","author":"Polzin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B103-20241015","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1160\/th14-04-0302","article-title":"The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting","volume":"112","author":"Breet","year":"2014","journal-title":"Thromb Haemost"},{"key":"B104-20241015","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.amjcard.2015.11.029","article-title":"Differences in whole blood platelet aggregation at baseline and in response to aspirin and aspirin plus clopidogrel in patient with versus without chronic kidney disease","volume":"117","author":"Jain","year":"2016","journal-title":"Am J Cardiol"},{"key":"B105-20241015","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1172\/JCI110824","article-title":"Reduced platelet thromboxane formation in uremia: Evidence for a functional cyclooxygenase defect","volume":"71","author":"Remuzzi","year":"1983","journal-title":"J Clin Invest"},{"key":"B106-20241015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"B107-20241015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"B108-20241015","first-page":"CD008834","article-title":"Antiplatelet agents for chronic kidney disease","author":"Palmer","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B109-20241015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","article-title":"Antithrombotic therapy in patients with chronic kidney disease","volume":"125","author":"Capodanno","year":"2012","journal-title":"Circulation"},{"key":"B110-20241015","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"B111-20241015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: A multicenter randomized clinical trial (AASER study)","volume":"32","author":"Goicoechea","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"B112-20241015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/hdi.12409","article-title":"Low-dose aspirin for prevention of cardiovascular disease in patients on hemodialysis: A 5-y prospective cohort study","volume":"20","author":"Liu","year":"2016","journal-title":"Hemodial Int"},{"key":"B113-20241015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2016.06.013","article-title":"Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis","volume":"251","author":"Major","year":"2016","journal-title":"Atherosclerosis"},{"key":"B114-20241015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11255-019-02350-8","article-title":"Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis","volume":"52","author":"Qu","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"B115-20241015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/11630740-000000000-00000","article-title":"Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications","volume":"51","author":"Floyd","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"B116-20241015","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y12- ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation"},{"key":"B117-20241015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"B118-20241015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B119-20241015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00044011-199816040-00006","article-title":"Clopidogrel activities in patients with renal function impairment","volume":"16","author":"Deray","year":"1998","journal-title":"Clin Drug Investig"},{"key":"B120-20241015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00228-018-2484-7","article-title":"Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function","volume":"74","author":"Teng","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"B121-20241015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2710.2009.01068.x","article-title":"Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease","volume":"34","author":"Small","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"B122-20241015","doi-asserted-by":"crossref","first-page":"e001683","DOI":"10.1161\/CIRCINTERVENTIONS.115.001683","article-title":"Prevalence and impact of high platelet reactivity in chronic kidney disease: Results from the assessment of dual antiplatelet therapy with drug-eluting stents registry","volume":"8","author":"Baber","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"B123-20241015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"B124-20241015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.kint.2016.09.014","article-title":"Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease","volume":"91","author":"Carrero","year":"2017","journal-title":"Kidney Int"},{"key":"B125-20241015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.hjr.0000220582.19516.a6","article-title":"Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel","volume":"14","author":"Keltai","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"B126-20241015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"155","author":"Best","year":"2008","journal-title":"Am Heart J"},{"key":"B127-20241015","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1093\/ndt\/gft103","article-title":"Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy","volume":"28","author":"Gremmel","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B128-20241015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjcvp\/pvv052","article-title":"Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting","volume":"2","author":"Guo","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B129-20241015","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur Heart J"},{"key":"B130-20241015","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"B131-20241015","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"B132-20241015","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"B133-20241015","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2215\/CJN.12120720","article-title":"Prasugrel and ticagrelor in patients with drug-eluting stents and kidney failure","volume":"16","author":"Mavrakanas","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B134-20241015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrneph.2013.83","article-title":"Chronic kidney disease: How effective and safe are antiplatelet agents in CKD?","volume":"9","author":"Floege","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B135-20241015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ahj.2020.04.013","article-title":"TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial","volume":"225","author":"Laine","year":"2020","journal-title":"Am Heart J"},{"key":"B136-20241015","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease"},{"key":"B137-20241015","doi-asserted-by":"crossref","first-page":"e012236","DOI":"10.1161\/JAHA.119.012236","article-title":"Safety of dual-antiplatelet therapy after myocardial infarction among patients with chronic kidney disease","volume":"8","author":"Rymer","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B138-20241015","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"B139-20241015","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.jacc.2016.03.485","article-title":"DAPT score utility for risk prediction in patients with or without previous myocardial infarction","volume":"67","author":"Kereiakes","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B140-20241015","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B141-20241015","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/ndt\/gfy387","article-title":"Performance of bleeding risk scores in dialysis patients","volume":"34","author":"Ocak","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B142-20241015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41581-018-0080-9","article-title":"Estimated GFR: Time for a critical appraisal","volume":"15","author":"Porrini","year":"2019","journal-title":"Nat Rev Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.04100321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:33Z","timestamp":1786369533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.04100321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04100321","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}